Lena Jendeberg
Directeur/Bestuurslid bij ATTANA AB
Profiel
Lena Jendeberg is currently working as a Director at Attana AB since 2018.
Prior to this, she worked as a Vice President-Development at Modus Therapeutics AB.
Dr. Jendeberg holds a doctorate degree from the Royal Institute of Technology.
Actieve functies van Lena Jendeberg
Bedrijven | Functie | Begin |
---|---|---|
ATTANA AB | Directeur/Bestuurslid | 01-01-2018 |
Eerdere bekende functies van Lena Jendeberg
Bedrijven | Functie | Einde |
---|---|---|
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Corporate Officer/Principal | - |
Opleiding van Lena Jendeberg
Royal Institute of Technology | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ATTANA AB | Health Services |
Bedrijven in privébezit | 1 |
---|---|
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Health Technology |